189 related articles for article (PubMed ID: 18026991)
21. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
22. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic value of urine-based survivin mRNA test using reverse transcription-polymerase chain reaction for bladder cancer: a systematic review.
Xia Y; Liu YL; Yang KH; Chen W
Chin J Cancer; 2010 Apr; 29(4):441-6. PubMed ID: 20346223
[TBL] [Abstract][Full Text] [Related]
25. Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma.
Srivastava R; Arora VK; Aggarwal S; Bhatia A; Singh N; Agrawal V
Diagn Cytopathol; 2012 Sep; 40(9):755-9. PubMed ID: 22888081
[TBL] [Abstract][Full Text] [Related]
26. The Effects of Instrumentation on Urine Cytology and CK-20 Analysis for the Detection of Bladder Cancer.
Wegelin O; Bartels DW; Tromp E; Kuypers KC; van Melick HH
Urology; 2015 Oct; 86(4):772-6. PubMed ID: 26166668
[TBL] [Abstract][Full Text] [Related]
27. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of hTERT, KRT7, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR.
Yahyazadeh R; Bashash D; Ghaffari P; Kord S; Safaroghli-Azar A; Ghaffari SH
BMC Urol; 2021 Apr; 21(1):64. PubMed ID: 33874920
[TBL] [Abstract][Full Text] [Related]
29. [Usefulness of survivin/glyceraldehyde-3-phosphate dehydrogenase ratio in urine exfoliated cells for the detection of bladder tumor].
Sakamoto Y; Nishioka J; Noma K; Yasuda K; Nakatani K; Kise H; Sugimura Y; Nobori T
Rinsho Byori; 2011 May; 59(5):446-51. PubMed ID: 21706857
[TBL] [Abstract][Full Text] [Related]
30. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
[TBL] [Abstract][Full Text] [Related]
31. Detection of urine survivin in 40 patients with bladder cancer.
Ohsawa I; Nishimura T; Kondo Y; Kimura G; Satoh M; Matsuzawa I; Hamasaki T; Ohta S
J Nippon Med Sch; 2004 Dec; 71(6):379-83. PubMed ID: 15673958
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.
Eissa S; Salem AM; Zohny SF; Hegazy MG
Cancer Biomark; 2007; 3(6):275-85. PubMed ID: 18048965
[TBL] [Abstract][Full Text] [Related]
33. Voided urine flow cytometry in screening high-risk patients for the presence of bladder cancer.
Hermansen DK; Badalament RA; Bretton PR; Kimmel M; Aswad CM; Whitmore WF; Melamed MR
J Occup Med; 1990 Sep; 32(9):894-7. PubMed ID: 2074515
[TBL] [Abstract][Full Text] [Related]
34. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
35. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.
Bialkowska-Hobrzanska H; Bowles L; Bukala B; Joseph MG; Fletcher R; Razvi H
Mol Diagn; 2000 Dec; 5(4):267-77. PubMed ID: 11172490
[TBL] [Abstract][Full Text] [Related]
36. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
37. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
38. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
[TBL] [Abstract][Full Text] [Related]
40. The clinical relevance of urine-based markers for diagnosis of bladder cancer.
Eissa S; Swellam M; Amin A; Balbaa ME; Yacout GA; El-Zayat TM
Med Oncol; 2011 Jun; 28(2):513-8. PubMed ID: 21437743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
